EGFR and non-small cell lung carcinoma: CNV landscapes of all genes in the NSCLC cases were showed in Fig. 2B. CNV rates of CDKN2A, myelocytomatosis oncogene (MYC), EGFR and cyclin-dependent kinases 4 (CDK4) genes in the NSCLC cohort were 15.9%, 12.4%, 8.2% and 7.4%, respectively.